Clinical Professor of Medicine, UCSF
Internal Medicine
Dr. Hope S. Rugo, MD
|
|
Give Review
Dr. Hope S. Rugo is an expert in the field of Internal Medicine. She attended Perelman School of Medicine at the University of Pennsylvania. She received 5 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Women's Health" and "Super Doctor". Hope Rugo is also a published MD. She has 99 publication published. The most recent publication is: A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Hope Rugo accepts Medicare.
Publications
- Meta-Analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
- A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
- Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
- HER2-positive breast Cancer: is more treatment better?
- Trends in the use of mastectomy in women with small node-negative breast Cancer treated at US academic centers.
- Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast Cancer previously treated with an anthracycline, a taxane, and capec...
- Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast Cancer: how the latest results are improving therapeutic options.
- Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast Cancer.
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Canc...
- Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
- Variation in type of adjuvant chemotherapy received among patients with stage I breast Cancer: A multi-institutional study.
- The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer.
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast Cancer.
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer.
- SIS.NET: A randomized controlled trial evaluating a web-based system for symptom management after treatment of breast Cancer.
- Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience.
- Circulating tumor cell analysis in metastatic triple-negative breast Cancers.
- Macrophage IL-10 Blocks CD8(+) T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in IntratumOral Dendritic Cells.
- Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-Negative Metastatic Breast Cancer in a Community Setting.
- A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast Cancer: translational breast Cancer research consortium tr...
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast Cancer: overall survival results from BOLER...
- Practice Patterns in the Delivery of Radiation Therapy After Mastectomy Among the University of California Athena Breast Health Network.
- Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with lo...
- The Cancer glycocalyx mechanically primes integrin-mediated growth and survival.
- Hormone therapy in premenopausal women with early-stage breast Cancer.
- Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast Cancer.
- Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study.
- Long-term survivor characteristics in HER2-positive metastatic breast Cancer from registHER.
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast Cancer.
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast Cancer: insights from BOLERO-2.
- Management of chemotherapy-induced nausea and vomiting in clinical practice.
- Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast Cancer in BOLERO-2.
- Informational Needs of Patients with Metastatic Breast Cancer: What Questions Do They Ask, and Are Physicians Answering Them?
- Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- New developments in metastatic breast Cancer: introduction.
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer.
- Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Health-Related Quality of Life and Disease Symptoms in Postmenopausal Women With HR(+), HER2(-) Advanced Breast Cancer Treated With Everolimus Plus Exemestane Versus E...
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast Cancer: Subgroup analysis from the BOLERO-2 study.
- Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast Cancer.
- Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials.
- Health-related quality of life of patients with advanced breast Cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomize...
- Impact of chemotherapy-induced nausea and vomiting.
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
- Time to adjuvant chemotherapy for breast Cancer in national comprehensive Cancer network institutions.
- Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast Cancer.
- Genomic profiling of isolated circulating tumor cells from metastatic breast Cancer patients.
- Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast Cancer.
- The impact of an electronic health questionnaire on symptom management and behavior reporting for breast Cancer survivors.
- Patient perceptions of reproductive health counseling at the time of Cancer diagnosis: a qualitative study of female California Cancer survivors.
- Reversing Hormone Resistance: Have We Found the Golden Key?
- The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression.
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: F...
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer.
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
- Associations Between Pro- and Anti-Inflammatory Cytokine Genes and Breast Pain in Women Prior to Breast Cancer Surgery.
- A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast Cancer.
- Immune microenvironments in solid tumors: new targets for therapy.
- Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer.
- Bisphosphonates and their impact on disseminated tumor cells in early stage breast Cancer.
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second...
- Breast Cancer Special Feature: Leukocyte composition of human breast Cancer.
- Reducing the long-term effects of chemotherapy in young women with early-stage breast Cancer.
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER.
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy.
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer.
- Systemic treatment of early breast Cancer--a biological perspective.
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast Cancer after prior H...
- Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast Cancer.
- Studying Cancer-related fatigue: report of the NCCN scientific research committee.
- Cost comparison of capecitabine in patients with breast Cancer.
- Amelioration of sexual adverse effects in the early breast Cancer patient.
- Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast Cancer.
- Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast Cancer.
- Triple-negative breast Cancer: role of antiangiogenic agents.
- Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast Cancer.
- Antiemesis. Clinical Practice Guidelines in Oncology.
- Lapatinib: new directions in HER2 directed therapy for early stage breast Cancer.
- A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast Cancer.
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast Cancer previously treated with an anthracycline...
- Quantitative and clinical description of postural instability in women with breast Cancer treated with taxane chemotherapy.
- Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
- Bevacizumab for advanced breast Cancer.
- Hormonal therapy for advanced breast Cancer.
- The role of trastuzumab in early stage breast Cancer: current data and treatment recommendations.
- The role of angiogenesis inhibition in the treatment of breast Cancer.
- Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an Oral angiogenesis inhibitor, in patie...
- Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid Tumors: pharmacokinetic and clinical results.
- MRI measurements of Breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
- High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell can...
- Patient and physician attitudes toward breast Cancer clinical trials: developing interventions based on understanding barriers.
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast Cancer.
- Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
- Bevacizumab in the treatment of breast Cancer: rationale and current data.
- The impact of adjuvant therapy for breast Cancer on cognitive function: current evidence and directions for research.
Schools
Univ Of Pa Sch Of Med
University Calif
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Women's Health
- Super Doctor
Education
-
UCSF -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
San Francisco General Hospital and Trauma Center -
San Francisco VA Medical Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1033176581 | |
| NPPES Provider LastName | RUGO | |
| NPPES Provider FirstName | HOPE | |
| NPPES Provider ZIPCode | 941153010 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 498.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033176581 |
| Last Name Of The Provider | RUGO |
| First Name Of The Provider | HOPE |
| View All |
Similar Doctors
|
|
Dr. Olivia W. Zachary, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shaun J. Young, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott J. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shelly Bar, MD |
|
|
Dr. Dan Ladabaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa Zacharewicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca Olin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Collin M. Blakely, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily K. Bergsland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald I. Abrams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan B. Glassberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas G. Martin III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sunny Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David H. Kirn, MD |
|
|
Dr. Jay A. Levy, MD |
|
|
Dr. Peter H. Sayre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hiromi Terawaki, MD |
|
|
Dr. Morris A. Flaum, MD |